BIT Capital’s Viking Therapeutics VKTX Stock Holding History

BIT Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-18,000	Closed	-$1.14M	–	143
2024 Q3	$1.14M	Sell	18,000 -4,500	-20%	-$264K	0.11%	66
2024 Q2	$1.19M	Buy	+22,500	New	+$1.47M	0.09%	69

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BIT Capital's VKTX Position: Q1 2025 in Review

BIT Capital sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 124,443 shares — an estimated $5.01M sold.

BIT Capital first reported a position in VKTX in Q1 2023 and held it in 5 quarters. The position peaked at $7.35M in Q3 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

BIT Capital reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
BIT Capital sold 124,443 Viking Therapeutics shares in Q1 2025, an estimated $5.01M.
BIT Capital first reported a position in Viking Therapeutics in Q1 2023 and held it in 5 quarters.
BIT Capital's Viking Therapeutics position peaked at $7.35M in Q3 2024.
372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on BIT Capital's 13F filing for Q1 2025, filed 9 May 2025.